CN1891699A - 用于治疗的吗啉代基取代的化合物 - Google Patents

用于治疗的吗啉代基取代的化合物 Download PDF

Info

Publication number
CN1891699A
CN1891699A CNA2006100847155A CN200610084715A CN1891699A CN 1891699 A CN1891699 A CN 1891699A CN A2006100847155 A CNA2006100847155 A CN A2006100847155A CN 200610084715 A CN200610084715 A CN 200610084715A CN 1891699 A CN1891699 A CN 1891699A
Authority
CN
China
Prior art keywords
compound
aryl
formulation
tgx
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006100847155A
Other languages
English (en)
Chinese (zh)
Inventor
A·D·罗伯森
S·杰克森
V·肯彻
C·艾普
H·帕拉巴哈兰
P·汤普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
KIENACIA CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KIENACIA CO Ltd filed Critical KIENACIA CO Ltd
Publication of CN1891699A publication Critical patent/CN1891699A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CNA2006100847155A 2000-01-24 2001-01-24 用于治疗的吗啉代基取代的化合物 Pending CN1891699A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17735100P 2000-01-24 2000-01-24
US60/177351 2000-01-24
US22582600P 2000-08-17 2000-08-17
US60/225826 2000-08-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB018067522A Division CN1263743C (zh) 2000-01-24 2001-01-24 用于治疗的吗啉代基取代的化合物

Publications (1)

Publication Number Publication Date
CN1891699A true CN1891699A (zh) 2007-01-10

Family

ID=26873182

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2006100847155A Pending CN1891699A (zh) 2000-01-24 2001-01-24 用于治疗的吗啉代基取代的化合物
CNA200610084723XA Pending CN1891693A (zh) 2000-01-24 2001-01-24 用于治疗的吗啉代基取代的化合物
CNB018067522A Expired - Fee Related CN1263743C (zh) 2000-01-24 2001-01-24 用于治疗的吗啉代基取代的化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA200610084723XA Pending CN1891693A (zh) 2000-01-24 2001-01-24 用于治疗的吗啉代基取代的化合物
CNB018067522A Expired - Fee Related CN1263743C (zh) 2000-01-24 2001-01-24 用于治疗的吗啉代基取代的化合物

Country Status (14)

Country Link
US (4) US6977255B2 (https=)
EP (2) EP1857443B1 (https=)
JP (1) JP4820518B2 (https=)
CN (3) CN1891699A (https=)
AT (2) ATE363471T1 (https=)
AU (2) AU2001230426C1 (https=)
CA (1) CA2398163C (https=)
CY (1) CY1108023T1 (https=)
DE (1) DE60128655T2 (https=)
DK (1) DK1257537T3 (https=)
ES (1) ES2286093T3 (https=)
NZ (1) NZ520300A (https=)
PT (1) PT1257537E (https=)
WO (1) WO2001053266A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789144A (zh) * 2016-08-12 2019-05-21 南京盖特医药技术有限公司 蛋白激酶调节剂

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ES2788383T3 (es) 2000-04-25 2020-10-21 Icos Corp Inhibidores de delta fosfatidilo-inositol 3-quinasa humana
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB2405093B (en) * 2001-08-14 2005-07-06 Cancer Rec Tech Ltd DNA-PK inhibitors
CN1551766A (zh) * 2001-09-05 2004-12-01 ������������ʽ���� 淋巴细胞活化抑制剂和自身免疫性疾病治疗剂
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
TWI314928B (en) 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
EP2311818B1 (en) * 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
JP4646626B2 (ja) * 2002-08-16 2011-03-09 アストラゼネカ アクチボラグ ホスホイノシチド３−キナーゼβの阻害
CN101260104A (zh) * 2002-08-16 2008-09-10 阿斯利康(瑞典)有限公司 抑制磷酸肌醇3-激酶β
KR101050700B1 (ko) * 2002-08-26 2011-07-20 다케다 야쿠힌 고교 가부시키가이샤 칼슘 수용체 조절 화합물 및 이의 용도
CA2508601A1 (en) 2002-12-06 2004-06-24 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
WO2004092154A1 (en) * 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
KR20070087266A (ko) * 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
EP1636212B1 (en) * 2003-06-05 2007-06-27 Warner-Lambert Company LLC Cycloalkylsulfanyl substituted benzo¬b|thiophenes as therapeutic agents
US20040259926A1 (en) * 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
MXPA05012894A (es) * 2003-06-05 2006-02-22 Warner Lambert Co Benzofuranos 3-sustituidos como agentes terapeuticos.
EP1654257B1 (en) 2003-08-13 2010-03-17 Kudos Pharmaceuticals Limited Aminopyrones and their use as atm inhibitors
JP2007504209A (ja) * 2003-09-04 2007-03-01 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ＰＩ３Ｋ阻害活性を有する治療薬としてのハロゲン置換ベンゾ（ｂ）チオフェン類
ES2285517T3 (es) * 2003-10-31 2007-11-16 Warner-Lambert Company Llc Pirimidinas como inhibidores de fosfoinositida-3-cinasas(pi3k).
US7855214B2 (en) * 2004-01-26 2010-12-21 Vertex Pharmaceuticals Incorporated Fused cyclic systems useful as inhibitors of TEC family protein kinases
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
CN1300163C (zh) * 2004-06-23 2007-02-14 南京大学 3－羟基色原酮糖苷及其制法和用途
TW200616986A (en) 2004-09-20 2006-06-01 Kudos Pharm Ltd DNA-pk inhibitors
JP2008529995A (ja) 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド Ａｔｍ阻害剤
AR054438A1 (es) 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
US7691858B2 (en) 2006-04-25 2010-04-06 Targegen, Inc. Kinase inhibitors and methods of use thereof
CA2656825C (en) * 2006-06-22 2013-12-10 Prana Biotechnology Limited Method of treatment and agents useful for same
US8106071B2 (en) * 2007-02-21 2012-01-31 Biobud Co., Ltd. Compositions for treating hyperproliferative vascular disorders and cancers
WO2008126920A1 (ja) 2007-04-11 2008-10-23 Ajinomoto Co., Inc. 糖尿病治療薬
WO2008150827A1 (en) * 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
US20100130597A1 (en) * 2007-07-06 2010-05-27 The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service Dna-pkcs modulates energy regulation and brain function
KR20100118977A (ko) * 2008-01-25 2010-11-08 아스트라제네카 아베 거울상이성질체적으로 순수한 (-) 2-[1-(7-메틸-2-(모르폴린-4-일)-4-옥소-4Ｈ-피리도[1,2-α]피리미딘-9-일)에틸아미노]벤조산, 의학 치료에서의 이의 용도 및 이를 포함하는 약학 조성물-026
EP2262366A4 (en) * 2008-04-18 2012-02-22 Shenogen Pharma Group Ltd COMPOUNDS AND METHODS FOR TREATING STROGEN RECEPTOR-RELATED DISEASES
US9326986B2 (en) 2008-09-29 2016-05-03 Glaxosmithkline Llc Quinazolinone, quinolone and related analogs as sirtuin modulators
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102271683B (zh) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
JP5680639B2 (ja) 2009-07-02 2015-03-04 サノフイ 新規６−モルホリン−４−イル−ピリミジン−４−（３ｈ）−オン誘導体、およびａｋｔ（ｐｋｂ）リン酸化阻害剤としてのこの医薬調製物
AR077364A1 (es) 2009-07-02 2011-08-24 Sanofi Aventis Derivados de 6-oxo-1,6- dihidro -pirimidin-2-il-) amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)
BRPI1015943A8 (pt) 2009-07-02 2018-01-09 Sanofi Sa derivados de 1,2,3,4-tetra - hidro - pirimido {1,2-a} pirimidin-6-ona, o respectivo preparo e a respectiva utilização farmacêutica.
ES2627428T3 (es) 2009-07-02 2017-07-28 Sanofi Nuevos derivados de 2,3-dihidro-1H-imidazo{1,2-a}pirimidin-5-ona, su preparación y su utilización farmacéutica
EA201270184A1 (ru) 2009-07-21 2012-08-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Лечение расстройств печени ингибиторами pi3k
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
IT1403156B1 (it) 2010-12-01 2013-10-04 Università Degli Studi Di Torino Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
FR2969613B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique
FR2969612B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
DK2655375T3 (en) 2010-12-23 2015-03-09 Sanofi Sa PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
PL2658844T3 (pl) 2010-12-28 2017-04-28 Sanofi Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb)
EP2808322B1 (en) * 2012-01-26 2017-08-23 Daiichi Sankyo Company, Limited Chromone derivative having osteogenesis promoting effect
EP2812004B1 (en) * 2012-02-10 2018-06-27 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
CA2865957C (en) 2012-03-01 2020-02-11 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
SI2834241T1 (sl) 2012-03-05 2021-06-30 Gilead Calistoga Llc Polimorfne oblike (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilkinazolin-4(3H)-ONA
CA2868026C (en) 2012-03-23 2021-02-16 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
ITMI20120514A1 (it) * 2012-03-29 2013-09-30 Cnr Consiglio Naz Delle Ric Erche Agente terapeutico per il trattamento dei vasi sanguigni
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
WO2015095601A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
EP3154960A1 (en) 2014-06-13 2017-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CN107635999B (zh) * 2015-05-20 2020-09-25 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的化合物
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
EA201800367A1 (ru) 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
US11129824B2 (en) 2015-12-17 2021-09-28 Biokine Therapeutics Ltd. Small molecules for inhibiting chemokine activity and/or cancer cells growth
WO2017103931A1 (en) 2015-12-17 2017-06-22 Biokine Therapeutics Ltd. Small molecules against cancer
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを調節する方法
EP3573619A4 (en) 2017-01-27 2020-10-28 SignalRX Pharmaceuticals, Inc. THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN AND CHECKPOINT INHIBITORS
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
JP2020523365A (ja) 2017-06-14 2020-08-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを改変する方法
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
EA202092001A1 (ru) 2018-03-27 2021-01-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни гентингтона
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
HRP20240935T1 (hr) 2018-06-27 2024-11-22 Ptc Therapeutics, Inc. Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti
CN109748914B (zh) * 2018-12-29 2021-05-25 上海珂臻医药科技有限公司 吡啶并嘧啶类化合物及其应用
JP7649257B2 (ja) 2019-05-13 2025-03-19 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
AU2020276793A1 (en) 2019-05-15 2022-01-20 Alonbio Ltd. Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
CN111533721B (zh) * 2020-05-15 2022-04-26 浙江大学 苯并吡喃酮或喹啉酮类化合物及其应用
EP4161926A4 (en) * 2020-06-03 2024-06-19 Yumanity Therapeutics, Inc. PYRIDOPYRIMIDINES AND THEIR METHODS OF USE
US20240166617A1 (en) * 2021-02-01 2024-05-23 Geode Therapeutics Inc. Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof
IL307950A (en) 2021-05-03 2023-12-01 Petra Pharma Corp Allosteric chromanone inhibitors of PHOSPHOINOSITIDE 3-KINASE (PI3K) for the treatment of diseases
MX2023013987A (es) 2021-05-27 2024-02-12 Petra Pharma Corp Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
US20250084048A1 (en) * 2021-10-07 2025-03-13 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
WO2025136936A1 (en) * 2023-12-19 2025-06-26 Merck Sharp & Dohme Llc Agonists of trem2 activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS604170A (ja) * 1983-06-21 1985-01-10 Nippon Shinyaku Co Ltd キノロン誘導体
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
WO1990006921A1 (en) 1988-12-21 1990-06-28 The Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH05509302A (ja) 1990-06-20 1993-12-22 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789144A (zh) * 2016-08-12 2019-05-21 南京盖特医药技术有限公司 蛋白激酶调节剂
CN109789144B (zh) * 2016-08-12 2022-04-15 马德拉医疗公司 蛋白激酶调节剂

Also Published As

Publication number Publication date
NZ520300A (en) 2004-05-28
JP2003530318A (ja) 2003-10-14
EP1857443B1 (en) 2012-03-28
DE60128655D1 (de) 2007-07-12
AU2001230426B2 (en) 2005-12-01
CY1108023T1 (el) 2013-09-04
CA2398163C (en) 2011-02-22
CA2398163A1 (en) 2001-07-26
EP1857443A2 (en) 2007-11-21
US20080312233A1 (en) 2008-12-18
DE60128655T2 (de) 2008-02-07
US20030216389A1 (en) 2003-11-20
JP4820518B2 (ja) 2011-11-24
EP1257537A1 (en) 2002-11-20
AU3042601A (en) 2001-07-31
WO2001053266A1 (en) 2001-07-26
EP1257537A4 (en) 2003-04-23
ATE551325T1 (de) 2012-04-15
US6977255B2 (en) 2005-12-20
US20050085471A1 (en) 2005-04-21
CN1891693A (zh) 2007-01-10
HK1051187A1 (en) 2003-07-25
EP1857443A3 (en) 2007-12-26
AU2001230426C1 (en) 2006-06-22
US7405211B2 (en) 2008-07-29
CN1418195A (zh) 2003-05-14
HK1115378A1 (en) 2008-11-28
EP1257537B1 (en) 2007-05-30
ES2286093T3 (es) 2007-12-01
US20080206312A1 (en) 2008-08-28
US7572791B2 (en) 2009-08-11
DK1257537T3 (da) 2007-10-01
CN1263743C (zh) 2006-07-12
ATE363471T1 (de) 2007-06-15
PT1257537E (pt) 2007-08-03

Similar Documents

Publication Publication Date Title
CN1891699A (zh) 用于治疗的吗啉代基取代的化合物
JP3885116B2 (ja) 蛋白チロシンキナーゼ媒介細胞増殖を抑制するためのピリド［２，３−ｄ］ピリミジン類
CN1023700C (zh) 芳族及杂环甲酰胺衍生物抗肿瘤剂的制备
EP2057153B1 (en) (3-aryl-piperazin-1-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline
KR101911560B1 (ko) 이온 채널 조정제로서의 융합된 헤테로시클릭 화합물
CN1283626C (zh) 取代苯衍生物或其盐
CN1281590C (zh) 具有抑制血管生成活性的六员氨基酰胺类衍生物
JPH06211855A (ja) アザキノキサリン類、それらの製造方法およびそれらの使用
JP5856086B2 (ja) 薬物製造のためのイソキノロン類の使用、新規なイソキノロン類およびそれらの合成方法
JP2021105002A (ja) イミダゾピリダジン化合物
JP2007015928A (ja) 新規オレフィン誘導体
CN101820879A (zh) 具有柔性侧链的抗疟用化合物
CN1823067A (zh) 具有抑制磷脂酰肌醇3－激酶活性的化合物及其使用方法
CN1726213A (zh) 作为腺苷a3受体配体的咪唑并喹啉衍生物
CN1688575A (zh) 抑制磷酸肌醇3－激酶β
CN101039943A (zh) 作为抗癌剂的新型吖吲哚噻唑啉酮
WO2001019818A1 (en) Phthalazinone derivatives as pd3/4 inhibitors
JP4853824B2 (ja) キノロン誘導体を有効成分とする医薬組成物
JPH059174A (ja) ぜん息、関節炎および関連疾患の治療に有用なテトラリンおよびクロマン誘導体
HK1051187B (en) Therapeutic morpholino-substituted compounds
WO2022037601A1 (zh) 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途
TW201943717A (zh) 類fms酪胺酸激酶抑制劑
WO2004048366A1 (ja) ２−オキソインドリン誘導体
CN1730475A (zh) 芳胺烯酮类化合物、其合成方法、含有其的药物组合物及用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ASTRAZENECA AB

Free format text: FORMER OWNER: KIENACIA CO. LTD.

Effective date: 20070921

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20070921

Address after: Swedish Sodertalje

Applicant after: Astrazeneca AB

Address before: Vitoria, Australia

Applicant before: Kienacia Co., Ltd.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070110